Introduction
Platinum-based anti-cancer therapeutics, including cisplatin, are widely used for the treatment of various human cancers, including lung, bladder, head and neck, ovarian, elucidate DDR, its regulatory mechanisms, and pathological role in cisplatin-AKI. It will also highlight renoprotective strategies by targeting DDR to reduce nephrotoxicity during cisplatin chemotherapy.
DNA damage caused by cisplatin
After entering the cell, cisplatin loses its chloride ligand due to the low intracellular chloride anionic concentration, resulting in the aquated forms of [Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2(OH2)2]2+ (Cepeda et al. 2007; Fujikawa et al. 2014; Wang and Lippard 2005) . Aquated cisplatin has a high affinity with DNA and binds DNA through the interaction of platinum atom and N7 position of purine bases leading to the formation of intrastrand crosslinks and interstrand crosslinks (Basu and Krishnamurthy 2010; Fujikawa et al. 2014; Wang and Lippard 2005) . 1,2-Intrastrand crosslinks can form by adjacent guanines(1,2-GpG) or adjacent adenine and guanine(1,2-ApG), whereas 1,3-intrastrand crosslinks are formed by non-adjacent guanines(1,3-GpNpG) and interstrand crosslinks by guanines (Fig. 2) . Among them, guanine-guanine intrastrand crosslinks (1,2-GpG) are the most common adducts caused by cisplatin. Altogether, these DNA crosslinks induce DNA double-helix disruption and further blockage of DNA replication and transcription (Ciccia and Elledge 2010; Fujikawa et al. 2014; Kruger et al. 2015; Roos and Kaina 2013; Wang and Lippard 2005) .
DNA damage response
In response to the formation of cisplatin-DNA crosslinks and adducts, the cell mounts a rapid DNA damage response-DDR. The current understanding of DDR is mainly based on the extensive studies on ataxia telangiectasia mutated (ATM) and ATM-and Rad-3-related (ATR) kinases, which are the key upstream regulators of cellular response to DNA damage (Cuadrado et al. 2006; Hurley and Bunz 2007; Jiang and Dong 2008; Ma et al. 2014; Myers et al. 2009; Pabla et al. , 2011b Zannini et al. 2014) . Essentially, these two protein kinases act as the "sensors" of DNA lesions, which, upon activation, can phosphorylate the "mediator" proteins (Ciccia and Elledge 2010; Cuadrado et al. 2006; Hurley and Bunz 2007; Kemp et al. 2011; Roos and Kaina 2013) . The mediators further recruit "transducer" kinases such as checkpoint kinase 1 (Chk1) and checkpoint kinase 2 (Chk2) for phosphorylation and activation (Hurley and Bunz 2007; Woods and Turchi 2013) . Finally, the "transducer" kinases phosphorylate their substrate proteins, called "effectors," which regulate multiple cellular responses, including DNA repair, cell cycle arrest, and cell death. One of the key effectors in DDR is p53 Wang et al. 2006; Wei et al. 2007 ). P53 induces cell cycle arrest and/or apoptosis in response to DNA damage by transcriptional and non-transcriptional mechanisms (Ciccia and Elledge 2010; Jiang and Dong 2008; Wang and Lippard 2005) .
In general, ATM responds to DNA double-strand break (Lovejoy and Cortez 2009) . ATM is recruited to DNA damage sites via MRN complex (mre11-rad50-nbs1) and then activates H2AX (a member of H2A histone family) (Guo et al. 2008; Jaamaa et al. 2010; Koike et al. 2008; Lovejoy and Cortez 2009; Paull and Lee 2005; Thomasova and Anders 2014; Woods and Turchi 2013) . With the help of activated H2AX, ATM phosphorylates Chk2, the cell cycle checkpoint kinase that induces G1/S and G2/M arrest ( Fig. 3a ) (Hurley and Bunz 2007; Thomasova and Anders 2014; Woods and Turchi 2013; Zannini et al. 2014) . The occurrence of G1/S phase arrest is mainly mediated by p53. After phosphorylation and activation by Chk2, p53 induces the expression of p21, a well-known cyclin-dependent kinase inhibitors (CDKI) that inactivates cyclin-dependent kinase 2 (CDK2) to prevent G1/S phase progression Miller et al. 2010; Oh et al. 2014; Price et al. 2004a Price et al. , 2009 Zannini et al. 2014) . Alternatively, Chk2 induces cell division cycle 25 homolog C (cdc25C) phosphorylation and translocation from nuclei to cytosol and, as a result, cdc25C can no longer activate CDK1 for G2/M phase progression and result in cell cycle arrest at G2/M (Silva et al. 2014; Thomasova and Anders 2014; Zannini et al. 2014) . Different from ATM, ATR is generally activated in response to single-strand DNA breaks and replication stress (Lovejoy and Cortez 2009; Thomasova and Anders 2014) . Here DNA lesions are initially detected by replication protein A (RPA), which then recruits ATR to the DNA damage site with the help of ATR-interacting protein (ATRIP). Meanwhile, there is a formation and activation of the 9-1-1 complex (containing Rad9, Hus1, and Rad1), which leads to the recruitment of topoisomerase II β-binding protein 1 (TOPBP1). Together with TOPBP1, ATR-ATRIP complex induces Chk1 phosphorylation and activation ( Fig. 3b ) (Lovejoy and Cortez 2009; Roos and Kaina 2013; Wang et al. 2013; Zannini et al. 2014) . Chk1 regulates DNA replication in S phase and G2/M transition Patil et al. 2013b; Wang et al. 2013; Woods and Turchi 2013) . In addition to phosphorylation, Chk1 may also be subjected to the regulation by alternative splicing forms. Recent work has discovered a short splicing form of Chk1, named Chk1-S, which interacts with and antagonizes Chk1. Interestingly, Chk1/Chk1-S interaction is disrupted by Chk1 phosphorylation. Therefore, in response to DNA damage, Chk1 is phosphorylated preventing the association of Chk1-S for a sustained activation of Chk1 ensuring cell cycle arrest and apoptosis Patil et al. 2013b) , and then, G2/M phase arrest occurs; besides, Chk1 also activates cdc25A to induce CDK1 and CDK2 inhibition, leading to G1/S, S, and G2/M phase arrest Patil et al. 2013b; Thomasova and Anders 2014) . Recently, the NIMA-related kinases (Neks) family member Nek1 and Nek8 are found to play roles in ATR/Chk1 pathway to induce cell cycle arrest (Choi et al. 2013; Jackson 2013; Patil et al. 2013a ).
DNA repair
DNA repair is a mechanism contributing to the cisplatin resistance of many tumor types, such as ovarian, testicular, head and neck, and non-small cell lung carcinomas (NSCLCs) (Bowden 2014) , and numerous studies show that nucleotide excision repair (NER) is an important DNA repair mechanism participating in DNA repair of cancer cells (Basu and Krishnamurthy 2010; Bowden 2014; Hlavin et al. 2010; Roos and Kaina 2013) . NER can recognize DNA lesion, then excise the abnormal bases, and replace them with newly synthesized bases. According to the repair sites, NER can be classified into two types: One is transcription-coupled repair (TCR) that prefers to repair the transcribed strand to ensure transcription efficiency, and the other is global genomic repair that repairs the whole DNA strand (Bowden 2014; Wang and Lippard 2005) . In Fig. 3 a ATM is recruited to DNA damage sites via MRN complex (mre11-rad50-nbs1) and then activates H2AX. With the help of activated H2AX, ATM phosphorylates Chk2. b RPA identifies DNA lesions and recruits ATR to the DNA damage site with the help of ATRIP. Meanwhile, 9-1-1 complex activates and recruits TOPBP1. Together with TOPBP1, ATR-ATRIP complex induces Chk1 phosphorylation and activation kidneys, DNA repair following cisplatin treatment has been rarely studied. The only available information is the expression of some proteins that have been implicated in DNA repair. For example, proliferating cell nuclear antigen (PCNA), GADD 45, and GADD153 are induced during cisplatin treatment of kidney cells. GADD45 plays a role in DDR, and overexpression of GADD45 was reported to have a cytoprotective role (Wang and Lippard 2005) . The growth arrest and DNA damage-inducible 45 (GADD45) and GADD153 can prevent cells from entering S phase and induce DNA excision repair. PCNA was shown to accumulate in the same tubular cells in the outer stripe of the outer medulla with p27, a protein that mediate G1/S and G2/M phase arrest by preventing CDK2, CDK4, and CDK6 activation (Zhou et al. 2004 ). These observations suggest a possible link of DDR, DNA repair, and cell cycle arrest.
DDR, as the early cellular response to DNA damage, is known to trigger DNA repair, cell cycle arrest as well as cell death. In kidney ischemia-reperfusion injury, ATM was recently shown to play a cytoprotective role through activating Chk2 (Zhou et al. 2004) , an observation that is consistent with the finding that ATM-deficient kidney tubule cells are more sensitive to cisplatin injury (Ma et al. 2014) . During cisplatin treatment of mice, ATM activity showed a marginal decrease, whereas ATR was activated, suggesting that ATM-mediated DNA repair may be inactivated during severe injury in kidneys. Although DNA repair in cisplatin-AKI remains elusive, we speculate that DNA repair mechanisms are induced in the early phase of injury but inactivated in the presence of severe or prolonged insult (Pabla et al. 2011b ).
Renal cell death
If the DNA damage is very severe, cells initiate the activation of apoptotic pathways to induce cell death (Thomasova and Anders 2014) . The downstream pathways can be classified into: p53-dependent pathways and p53-independent pathways.
P53-dependent apoptosis

Upstream activators of p53
As is discussed above, ATM and ATR can activate Chk2 and Chk1 to modulate cell cycle arrest. Do they also play a role in cisplatin-induced renal cell apoptosis?
In rat kidney proximal tubular cell line (RPTC), ATM is cleaved in the late stage of cisplatin treatment . Consistently, ATM degradation or activity decrease was shown in kidney tissues after cisplatin treatment . By sharp contrast, ATR is activated during cisplatin treatment and participates in renal cell apoptosis. In this regard, we reported that hMSH2, a mismatch repair protein, accumulates to DNA damage site during cisplatin treatment and further recruits ATR-ATRIP complex to activate Chk2, which then phosphorylate p53 to induce further apoptosis (Pabla et al. 2011b ). In other cell types, very recent work also demonstrated MSH2 induction by cisplatin (Zhang et al. 2013) . Classically, ATR is known to be a upstream regular of Chk1 and the ATR-Chk1 signaling axis induces S phase arrest under DNA damage to play a cytoprotective role (Hurley and Bunz 2007; Lovejoy and Cortez 2009; Wang et al. 2013) . Therefore, the recent studies indicate that there are two ATR pathways-hMSH2-dependent pathway that activates Chk2 and RPA-dependent pathway that activates Chk1. Notably, these two pathways lead to different outcomes-the first one leads to apoptosis, whereas the second leads to cell cycle arrest followed by DNA repair and resistance to cell death (Pabla et al. 2011b ).
Downstream effector of p53 pathway
The role of p53, a well-known tumor suppressor protein, in cisplatin-AKI has been well established by various pharmacological and genetic inhibitory studies (Basu and PUMA (p53-upregulated modulator of apoptosis) is a proapoptotic protein that has been shown to be induced via p53 in both in vitro and in vivo models of cisplatin-AKI (Jiang et al. 2006; Tsuruya et al. 2008; Zhang et al. 2014) . Upon induction, PUMA accumulates in mitochondria, where it interacts and suppresses the anti-apoptotic protein Bcl-xl, leading to the activation of the proapoptotic protein Bax, followed by cytochrome C release from mitochondria to activate caspases for apoptosis (Basu and Krishnamurthy 2010; Jiang and Dong 2008; Jiang et al. 2006; Nakano and Vousden 2001; Tsuruya et al. 2008) .
Other than PUMA, PIDD (p53-induced protein with death domain) was also reported to play a role downstream of p53 to induce kidney cell apoptosis. PIDD was shown to be induced by cisplatin via p53 and then interacts with RIP-associated Ich-1/Ced-3 homologous protein with a death domain (RAIDD) to recruit procaspase 2 to trigger the release of apoptosis-inducing factor (AIF) and Endo G from mitochondria. AIF then translocates to nucleus to induce cell death in a caspase-independent way Price et al. 2009; Seth et al. 2005) .
It is important to point out that p53 may also activate mechanisms of cell survival Price et al. 2009; Zannini et al. 2014) . This is well exemplified by the induction of p21, a CDK2 inhibitor. By antagonizing CDK2, p21 is known to be a cell cycle inhibitor (Miyaji et al. 2001; Price et al. 2006) . However, the induction of p21 by p53 has also been shown to be cytoprotective (Megyesi et al. 1998 ). Essentially, p21 may antagonize CDK2 to block its apoptotic signaling (Hodeify et al. 2011; Price et al. 2004b) . Interestingly, there is a novel feedback mechanism whereby CDK2 may phosphorylate p21 to block its inhibitory effect on CDKs (Hodeify et al. 2011) . Therefore, the fine balance between p21 and CDK2 plays an important role in determining cell death or survival in cisplatin-AKI. In addition to p21, p53 may also induce autophagy during cisplatin-AKI (PeriyasamyThandavan et al. 2008) . Autophagy is a critical mechanism for kidney cell survival and protection in AKI (Livingston and Dong 2014). Thus, by inducing autophagy, p53 may activate another mechanism of kidney protection. It remains unclear how and why p53 activates both mechanisms of cell survival and cell death. We speculate that the role of p53 in cisplatin-AKI depends on the experimental condition and cellular context: In early stage of injury or under mild-to-moderate injury, p53 may mainly activate the mechanism of cell survival; however, when the injury is severe and prolonged, cell death mechanisms become activated and predominant.
c-Abl-dependent apoptosis
Besides p53, cisplatin can also activate c-Abl via the mismatch repair (MMR) system to induce cell death (Basu and Krishnamurthy 2010; Kim et al. 2007; Li 2008; Shimodaira et al. 2003) . MMR is a highly conserved pathway generally known for DNA repair by detecting and binding to DNA lesion site for cytoprotection (Li 2008; Shimodaira et al. 2003; Stojic et al. 2004) . However, recent studies suggest that MMR may also participate in cisplatin-induced cell apoptosis (Nehme et al. 1999; Wang and Lippard 2005) .
During cisplatin treatment, c-Abl may be activated via ATM-mediated phosphorylation. It has been shown that MutSα can identify DNA lesion site and bind to it under the help of MutLα, recruiting the MMR complex with ATM, which then phosphorylate c-Abl (Guggenheim et al. 2009; Preyer et al. 2007; Tang et al. 2012; Topping et al. 2009; Vasquez 2010; Wang 2000) . Upon phosphorylation, c-Abl is transported into the nucleus to function. In this regard, genetic disruption of c-Abl nuclear import decreases renal cell death in cisplatin therapy (Preyer et al. 2007; Sridevi et al. 2013) . Intriguingly, normally c-Abl is sequestered in the cytosol by 14-3-3 proteins and, upon cisplatin treatment, c-Jum N-terminal kinase (JNK) is activated to interact with 14-3-3 proteins resulting in the release c-Abl for its import to the nucleus (Jiang et al. 2011; Levy et al. 2008; Toh et al. 2004; Yoshida 2008; Yoshida and Miki 2005) .
How does c-Abl induce cell death? Several studies have suggested the involvement of p73 (a p53 family member) in mediating the effect of c-Abl (Di et al. 2013; Shimodaira et al. 2003; Stojic et al. 2004 ). C-Abl may activate p73 by different pathways. It has been shown that c-Abl can phosphorylate Yes kinase-associated protein 1 (YAP-1), which then interacts with p63 to release p73 for activation (Gonfloni et al. 2009; Levy et al. 2007 Levy et al. , 2008 Yuan et al. 2010) . In addition, c-Abl may activate p73 in a p38 mitogen-activated protein kinase (p38 MAPK)-dependent manner, and c-Abl may also directly phosphorylate and activate p73 (Sanchez-Prieto et al. 2002) . Finally, nuclear c-Abl may associate with MEK kinase 1 (MEKK-1) to activate JNK for p73 activation (Francescato et al. 2007; Kharbanda et al. 2000; Sanchez-Prieto et al. 2002) . It is noteworthy that the role and regulation of the c-Abl pathway are largely unknown in cisplatin-AKI (Fig. 4) .
Targeting DNA damage response for renoprotection during cisplatin treatment
Cisplatin and related platinum compounds bind to DNA to induce crosslinks and adducts, resulting in DNA damage and replication stress. In response, the affected cells activate DDR. On the one hand, DDR may arrest cell cycle and promote DNA repair; on the other hand, it activates various signaling pathways to culminate in cell death. In kidneys, cisplatin-induced DDR has been delineated, which consists of the sequential activation of ATR, Chk2, p53, and downstream target genes. However, the information remains partial. It remains unclear whether and to what extents ATM and Chk1 contribute. Also DNA repair may be activated, at least at the early stage of cisplatin treatment or in response to mild-to-moderate levels of injury. Little is known about how DNA repair is activated and regulated. In addition, it is elusive as to how the DNA damage and DNA repair pathways interact and are tilted to dictate the fate of the affected cell.
Therapeutically, a number of pharmacological and genetic approaches have been shown to block DDR at various signaling levels for the protection of kidney cells and tissues during cisplatin treatment (Hodeify et al. 2011; Jiang et al. 2006 Jiang et al. , 2007 Kang et al. 2011; Sahu et al. 2013; Sridevi et al. 2013) . Currently, the focus is mainly at preventing kidney cells from injury and death. But, as alluded above, it would also be possible to prevent cisplatin-AKI by enhancing DNA repair, which apparently depends on 1 3 further investigation and elucidation of the underlying signaling pathways.
As we proposed in 2008 , an effective renoprotective approach has to be evaluated in tumor-bearing conditions. This is because many renoprotective agents may also protect tumor or cancer cells and, as a result, attenuate the chemotherapy effect of cisplatin, making it an invalid approach for cancer patients. This thought has to be applied, when considering targeting DDR for renoprotection during cisplatin therapy. In cancer cells, cisplatin stimulates DDR; therefore, an overall or blunt inhibition of DDR would block cell death in tumors and reduce or eliminate the cancer therapy effect of cisplatin. Then, how to make use of the information of DDR for renoprotection during cisplatin chemotherapy? First, it may be possible to locally deliver DDR inhibitory agents to kidneys. Experimentally, it can be done by invasive methods including direct injection to kidneys, which nevertheless are hard to apply to patients. Alternatively, it is possible to engineer kidney-directed agents by conjugating DDR inhibitors with kidney-specific molecules. Second, some of the genes in DDR are deleted or mutated in cancers. For example, p53 is deleted or mutated in over a half of cancers. In patients with these cancers, blockade of p53 may provide renoprotection without affecting cisplatin therapy in cancers. Finally, it is important to further investigate and identify the critical differences between the DDRs in cancer cells and kidney cells. With that information, we will be able to design strategies that specifically suppress the cell killing signaling in kidney cells without blocking that in cancer cells. In this aspect, recent studies have offered interesting insights. For example, blockade of protein kinase C δ (PKCδ) has been shown to protect kidney cells without diminishing the chemotherapy efficacy of cisplatin; as a mater of fact, the chemotherapy effect is enhanced in several types of experimental tumors (Pabla et al. 2011a ).
